We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gabapentin Recall Initiated Due to Excessive Impurities
Gabapentin Recall Initiated Due to Excessive Impurities
December 5, 2007
Ranbaxy Pharmaceuticals initiated a voluntary Class III recall of 73 million gabapentin tablets because the allowed level of impurities in the tablets may exceed their specification limits during shelf life, according to FDA documents.